Myelodysplastic Syndromes (MDS) (NHLBI-MDS) Observational

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Suspected (e.g., persistent unexplained cytopenia, circulating peripheral blasts etc.) MDS or MDS/MPN overlap disorders and undergoing diagnostic workup with planned bone marrow assessments, or diagnosed with de novo or therapy-related MDS within 6-months of enrollment per the World Health Organization (WHO) criteria and undergoing clinical evaluation and planned bone marrow assessments to confirm MDS or to evaluate disease status.
• Bone marrow aspirate expected to be performed within 1 week of registration, and in all cases must be performed no later than 4 weeks after enrollment.
• Age 18 or older.
• B12 level, serum folate, ferritin, and Thyroid-Stimulating Hormone (TSH) tests performed in prior 6 months.

A patient will not be eligible for participation in this study if any of the following criteria apply.

• Prior treatment for MDS at entry and through the time of the entry bone marrow aspirate.
• Treatment with hematopoietic growth factors in prior 6 months.
• Diagnosis of a solid tumor or hematologic malignancy within two years prior to enrollment except for in situ cancer of the skin (basal or squamous cell), cervix, bladder, breast or prostate.
• Treatment with radiation therapy in the two years prior to registration.
• Non-hormonal treatment for malignancy within the two years prior to registration.
• Established hereditary bone marrow failure syndrome.
• Known primary diagnosis of aplastic anemia, classical paroxysmal nocturnal hemoglobinuria, amegakaryocytic thrombocytopenic purpura, or large granular lymphocyte leukemia.
• Enrolled in the Connect® MDS/AML Disease Registry (NCT01688011).

To learn more, visit ClinicalTrials.Gov

Study Type

Observational

Principal Investigator(s)

Amanda Hathaway, MD

Sponsor(s)

ECOG-ACRIN Cancer Research Group